Department of Research Oncology, Division of Cancer Studies, King's College London, London, UK.
Target Oncol. 2009 Sep;4(3):169-81. doi: 10.1007/s11523-009-0118-9. Epub 2009 Oct 30.
Consider a single agent capable of diagnosing cancer, treating it simultaneously and monitoring response to treatment. Particles of this agent would seek cancer cells accurately and destroy them without harming normal surrounding cells. Science fiction or reality? Nanotechnology and nanomedicine are rapidly growing fields that encompass the creation of materials and devices at atomic, molecular and supramolecular level, for potential clinical use. Advances in nanotechnology are bringing us closer to the development of dual and multi-functional nanoparticles that are challenging the traditional distinction between diagnostic and treatment agents. Examples include contrast agents capable of delivering targeted drugs to specific epithelial receptors. This opens the way for targeted chemotherapy which could minimise systemic side-effects, avoid damage to benign tissues and also reduce the therapeutic treatment dose of a drug required. Most of the current research is still at the pre-clinical stage, with very few instances of bench to bedside research. In order to encourage more translational research, a fundamental change is required to consider the current clinical challenges and then look at ways in which nanotechnology can address these.
设想有一种能够诊断癌症的单一药物,同时对其进行治疗并监测治疗反应。这种药物的颗粒能够准确地寻找癌细胞并将其摧毁,而不会伤害正常的周围细胞。这是科幻还是现实?纳米技术和纳米医学是快速发展的领域,涵盖了原子、分子和超分子水平的材料和设备的创建,以用于潜在的临床应用。纳米技术的进步使我们更接近于开发双功能和多功能纳米颗粒,这些颗粒正在挑战诊断和治疗剂之间的传统区别。例如,能够将靶向药物递送到特定上皮受体的造影剂。这为靶向化疗开辟了道路,靶向化疗可以最大限度地减少全身副作用,避免对良性组织的损害,还可以降低所需药物的治疗剂量。目前的大部分研究仍处于临床前阶段,只有极少数的基础研究转化为临床研究。为了鼓励更多的转化研究,需要进行根本性的改变,既要考虑当前的临床挑战,又要着眼于纳米技术如何解决这些问题。